You are here

Article Text

Article menu
Download PDFPDF
PostScript
Correspondence
The Authors' reply
  1. Renicus S Hermanides,
  2. Arnoud W J van 't Hof
  1. Isala Klinieken, Department of Cardiology, Zwolle, The Netherlands
  1. Correspondence to Arnoud W J van 't Hof, Isala klinieken, Department of Cardiology, Groot Wezenland 20, Zwolle 8011 JW, The Netherlands; v.r.c.derks{at}isala.nl

https://doi.org/10.1136/heartjnl-2011-300220

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    We thank Dr Lin and colleagues1 for their comments regarding the outcomes of 30-day major adverse cardiac events (MACE) in the pre-defined subgroup analysis of the Ongoing Tirofiban In Myocardial infarction Evaluation 2 trial (On-TIME 2).2 There are different aspects of their comments that can be addressed.

    First, although prehospital use of high dose tirofiban reduces the use of bail-out study medication, and this need for bail-out study medication was associated with a less …

    View Full Text

    Footnotes

    • Competing interests None.

    • Provenance and peer review Not commissioned; not externally peer reviewed.